Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome

2007 ◽  
Vol 112 (12) ◽  
pp. 625-625
Author(s):  
G. F. Watts ◽  
J. Ji ◽  
D. C. Chan ◽  
E. M. M. Ooi ◽  
A. G. Johnson ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Plasma Lipid ◽  
Lipid Transfer ◽  
Lipid Transfer Proteins ◽  
The Metabolic Syndrome ◽  
Fenofibrate Treatment

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome

2006 ◽  
Vol 111 (3) ◽  
pp. 193-199 ◽  
Author(s):  
Gerald F. Watts ◽  
Juying Ji ◽  
Dick C. Chan ◽  
Esther M. M. Ooi ◽  
Anthony G. Johnson ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Low Density Lipoprotein ◽  
Plasma Lipid ◽  
Density Lipoprotein ◽  
Low Density ◽  
Lipid Transfer ◽  
Transfer Protein ◽  
The Metabolic Syndrome ◽  
Pltp Activity

The aim of the present study was to investigate the association between changes in apoB (apolipoprotein B-100) kinetics and plasma PLTP (phospholipid transfer protein) and CETP (cholesteryl ester transfer protein) activities in men with MetS (the metabolic syndrome) treated with fenofibrate. Eleven men with MetS underwent a double-blind cross-over treatment with fenofibrate (200 mg/day) or placebo for 5 weeks. Compared with placebo, fenofibrate significantly increased the FCRs (fractional catabolic rates) of apoB in VLDL (very-low-density lipoprotein), IDL (intermediate-density lipoprotein) and LDL (low-density lipoprotein) (all P<0.01), with no significant reduction (−8%; P=0.131) in VLDL-apoB PR (production rate), but an almost significant increase (+15%, P=0.061) in LDL-apoB PR. Fenofibrate significantly lowered plasma TG [triacylglycerol (triglyceride); P<0.001], the VLDL-TG/apoB ratio (P=0.003) and CETP activity (P=0.004), but increased plasma HDL (high-density lipoprotein)-cholesterol concentration (P<0.001) and PLTP activity (P=0.03). The increase in PLTP activity was positively associated with the increase in both LDL-apoB FCR (r=0.641, P=0.034) and PR (r=0.625, P=0.040), and this was independent of the fall in plasma CETP activity and lathosterol level. The decrease in CETP activity was positively associated with the decrease in VLDL-apoB PR (r=0.615, P=0.044), but this association was not robust and not independent of changes in PLTP activity and lathosterol levels. Hence, in MetS, the effects of fenofibrate on plasma lipid transfer protein activities, especially PLTP activity, may partially explain the associated changes in apoB kinetics.

scholarly journals Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study

2013 ◽  
Vol 228 (1) ◽  
pp. 230-236 ◽  
Author(s):  
Sander J. Robins ◽  
Asya Lyass ◽  
Robert W. Brocia ◽  
Joseph M. Massaro ◽  
Ramachandran S. Vasan
Keyword(s):  
Cardiovascular Disease ◽  
Framingham Heart Study ◽  
Plasma Lipid ◽  
Lipid Transfer ◽  
Lipid Transfer Proteins ◽  
Heart Study

The Apolipoprotein B/Apolipoprotein AI Ratio in the Metabolic Syndrome—Should We Start Using It?

2008 ◽  
Vol 3 (1) ◽  
pp. 53-54 ◽  
Author(s):  
Justo Sierra-Johnson ◽  
Abel Romero-Corral ◽  
Virend K. Somers ◽  
Francisco Lopez-Jimenez
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Apolipoprotein Ai ◽  
The Metabolic Syndrome

scholarly journals Plasma Markers of Cholesterol Homeostasis and Apolipoprotein B-100 Kinetics in the Metabolic Syndrome

2003 ◽  
Vol 11 (4) ◽  
pp. 591-596 ◽  
Author(s):  
Dick C. Chan ◽  
Gerald F. Watts ◽  
P. Hugh R. Barrett ◽  
Frans H. O'Neill ◽  
Gilbert R. Thompson
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Cholesterol Homeostasis ◽  
The Metabolic Syndrome ◽  
Plasma Markers

Autoantibodies against modified apolipoprotein B-100 in relation to low-density lipoprotein size and the metabolic syndrome in otherwise healthy men

Metabolism ◽  
2008 ◽  
Vol 57 (3) ◽  
pp. 362-366 ◽  
Author(s):  
Per Sjögren ◽  
Gunilla N. Fredrikson ◽  
Magdalena Rosell ◽  
Ulf de Faire ◽  
Anders Hamsten ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Apolipoprotein B ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Healthy Men ◽  
The Metabolic Syndrome ◽  
Lipoprotein Size
Sign in / Sign up

Export Citation Format

Share Document